"10.1371_journal.pone.0138503","plos one","2015-09-23T00:00:00Z","Antonia Lepida; Massimo Colombo; Inmaculada Fernandez; Djamal Abdurakhmanov; Paulo Abrao Ferreira; Simone I Strasser; Petr Urbanek; Alessandra Mangia; José L Calleja; Wafae Iraqi; Ralph DeMasi; Isabelle Lonjon-Domanec; Christophe Moreno; Heiner Wedemeyer","Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium; Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy; Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid, Spain; I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow, Russia; Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo, Brazil; AW Morrow Gastroenterology and Liver Center, Royal Prince Alfred hospital and University of Sydney, Sydney, Australia; Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague, Czech Republic; Liver Unit, IRCCS Hospital Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; Gastroenterology, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain; Janssen Pharmaceuticals, Paris, France; Janssen Research and development, Titusville, New Jersey, United States of America; Medizinische Hochschule Hannover, Hannover, Germany","Conceived and designed the experiments: MC. Performed the experiments: AL MC IF DA PAF SIS PU AM JLC CM HW. Analyzed the data: RD. Contributed reagents/materials/analysis tools: AL MC IF DA PAF SIS PU AM JLC WI RD IL-D CM HW. Wrote the paper: AL MC IF DA PAF SIS PU AM JLC WI RD IL-D CM HW.","The authors of this manuscript have read the journals policy and have the following competing interests: This study was funded by Janssen Pharmaceuticals. IL-D, WI and RD are employees of Janssen. The authors also acknowledge Stephanie Gibson (Zoetic Science, an Ashfield Company, part of UDG Healthcare plc, Macclesfield, UK) for editing and co-ordination support, which was funded by Janssen Pharmaceuticals. AL: No conflicts of interest. MC: Grant and research support: BMS, Gilead Science; Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science, Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck, GSK, GenSpera, AbbVie, AlfaWasserman, Jennerex; Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead Science, Vertex, Merck, Janssen, Sanofi. IF: Janssen: Speakers bureau; Gilead, MSD, Roche: Speakers bureau. DA: Speaker and had grants for lectures and clinical trials from Merck, Janssen, Roche, Novartis, BMS. PAF: Speaker and Clinical Investigator to Roche, Abbvie, Janssen, BMS, Boheringer, Merck, Gilead. SIS: Speaker and advisor: Janssen, MSD, Roche, BMS, Gilead Sciences, Abbvie, Bayer, Norgine. PU: No conflicts of interest regarding the topic of manuscript. CM: Speaker or adviser for Abbvie, MSD, Janssen, Bristol-Myers Squibb and Gilead Sciences pharmaceutical companies. Research Grant from MSD, Janssen, Astellas, Gilead Sciences, Novartis and Roche pharmaceutical companies. AM: Consultant for Gilead Sciences, Abbvie, Speaker bureau for Janssen, Gilead, ROCHE, MSD, Research grant for Gilead, ROCHE, MSD. JLC: Speaker or adviser for Abbvie, MSD, Roche, Janssen, Bristol-Myers Squibb and Gilead Sciences pharmaceutical companies. A Hill: Consultant for Janssen. HW: Honoraria for consulting and/or lectures: Abbvie, Abbott, Achillion, BMS, Gilead, Janssen, MSD, Novartis, Roche, Roche Diagnostics, Siemens, Transgene. Grant support: Roche, BMS, MSD. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2015","09","Antonia Lepida","AL",14,TRUE,1,11,1,14,TRUE,FALSE,FALSE,0,NA,FALSE
